Acrylonitrile: in vivo cytogenetic studies in mice and rats.
Acrylonitrile (VCN), a suspect human carcinogen, does not produce significant increases in cytogenetic aberrations in the mouse-bone marrow when given orally for 4, 15 or 30 days at doses equal to 7, 14 and 21 mg/kg/day resp. or by i.p. for the same time periods at doses of 10, 15 and 20 mg/kg/day. Rats treated orally with 16 daily doses of VCN (40 mg/kg/day) or potassium cyanide (KCN) (5 mg/kg/day) showed no increase of aberrant metaphases in the bone marrow over controls.
D000181:Acrylonitrile / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001853:Bone Marrow / Q000648:ultrastructure; D002869:Chromosome Aberrations; D004750:Enteral Nutrition; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D009570:Nitriles / Q000494:pharmacology*; D011190:Potassium Cyanide / Q000494:pharmacology; D051381:Rats
D009570:Nitriles; D000181:Acrylonitrile; D011190:Potassium Cyanide